<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and prevention of infections associated with anti-B-cell agents used for treatment of non-malignant medical conditions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and prevention of infections associated with anti-B-cell agents used for treatment of non-malignant medical conditions</h1>
<div class="graphic"><div class="figure"><div class="ttl">Evaluation and prevention of infections associated with anti-B-cell agents used for treatment of non-malignant medical conditions</div><div class="cntnt"><table cellspacing="0"><colgroup span="1" width="10%"></colgroup> <colgroup span="5" width="18%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Effect on immune system</td> <td class="subtitle1">Associated infections<sup>*</sup></td> <td class="subtitle1">Pre-treatment testing<sup>¶</sup></td> <td class="subtitle1">Pre-treatment vaccinations<sup>Δ</sup> </td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Rituximab</td> <td rowspan="3">Induces apoptosis of CD20+ B cells leading to disruption of B and T cell interaction.</td> <td rowspan="4">Bacterial: <ul class="decimal_heading"> <li>Tuberculosis and other mycobacterial infections</li> </ul> <p class="extra_spacing_top">Viral:</p> <ul class="decimal_heading"> <li><strong>HBV</strong></li> <li>HCV</li> <li>EBV and CMV</li> <li>Herpes zoster virus</li> <li>COVID-19 (except belimumab)</li> <li><strong>PML (JCV reactivation) (only rituximab)</strong></li> </ul> <p class="extra_spacing_top">Fungal:</p> <ul class="decimal_heading"> <li>Endemic mycoses</li> <li>Cryptococcal infection</li> <li><em>Pneumocystis</em> pneumonia (only rituximab)<sup>◊</sup></li> </ul> </td> <td rowspan="4">Test for: <ul class="decimal_heading"> <li>TBI</li> <li>HBV</li> <li>HCV</li> </ul> </td> <td rowspan="4"> <ul> <li>Routine age-appropriate vaccinations</li> <li>Pneumococcal vaccine(s)</li> <li>RZV</li> </ul> </td> <td rowspan="3"> <ul> <li>Out of the mentioned anti-B cell therapies, rituximab is associated with the highest risk of serious infections.</li> <li>When administering vaccines during therapy, some experts choose to delay dosing of rituximab by 2 weeks after administration of a vaccine to optimize immunogenicity of the vaccine.</li> <li>Some experts choose to initiate <em>Pneumocystis</em> prophylaxis in patients taking rituximab monotherapy, although overall risk is low.</li> </ul> </td> </tr> <tr> <td>Ocrelizumab</td> </tr> <tr> <td>Ofatumumab</td> </tr> <tr> <td>Belimumab</td> <td>Prevents stimulation of B cells but does not deplete them as the other agents do, leading to less risk of severe infection.</td> <td> <ul> <li>Belimumab is less likely to increase risk for serious infections compared with other anti B-cell agents.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table serves as an overview of how to evaluate for and prevent infections in patients starting and/or taking anti-B-cell agents for treatment of non-malignant medical conditions. Infections highlighted in bold have been specifically associated with anti-B-cell agents and warrant extra consideration.</div><div class="graphic_footnotes"><p>COVID-19: severe coronavirus disease 2019;
    CMV: cytomegalovirus;
    EBV: Epstein-Barr virus;
    HBV: hepatitis B virus;
    HCV: hepatitis C virus;
    HIV: human immunodeficiency virus;
    JCV: John Cunningham virus;
    PML: progressive multifocal leukoencephalopathy; RZV: recombinant (non-live) zoster vaccine (Shingrix);
    TBI: tuberculosis infection.</p>
<p>* In addition to the infections listed, typical, common bacterial and viral infections should also be considered in the differential when infection is suspected in a patient taking the specified agent.</p>
<p>¶ For patients who do not have a negative HIV test documented in their records or are at increased risk of acquiring HIV (eg, men who have sex with men, engagement in sex work), the pre-treatment infectious testing process is a good opportunity to provide routine HIV screening prior to the initiation of immunosuppression. Treat any infections found on pre-treatment testing. Control of infection should be demonstrated prior to initiating immunosuppressive therapy.</p>
<p>Δ Live and non-live vaccines should be administered no later than 4 and 2 weeks, respectively, prior to initiating therapy. Vaccine responses may be attenuated while on therapy and for 6 to 12 months after cessation of therapy.</p>
    ◊ Risk of <em>pneumocystis</em> pneumonia in patients taking rituximab for non-malignancy medical conditions is unclear. <em>Pneumocystis</em> pneumonia prophylaxis may be indicated when rituximab is used for certain conditions, such as vasculitis. Refer to UpToDate text on <em>Pneumocystis</em> pneumonia prophylaxis in patients without HIV for further details.</div><div id="graphicVersion">Graphic 143348 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
